Alphatec Holdings is trading 5% down now at $9.05 after extending its negative reaction to the August 4 earnings report, with investors concerned about a non-GAAP EPS miss, decelerating growth, and pressure on revenue per procedure.

  • Second-quarter revenue reached $214 million, and adjusted EBITDA guidance increased to $140 million.
  • The stock fell 7.54% to $9.57 on August 5, while healthcare gained 1.31%, indicating company-specific weakness.